Jennifer Woyach, MD

Articles

Dr. Woyach on the Safety Profiles of BTK Inhibitors in CLL

June 18th 2020

Jennifer Woyach, MD, discusses the safety profiles of BTK inhibitors in patients with chronic lymphocytic leukemia.

Dr. Woyach on the Utility of Time-Limited Therapies in CLL

April 9th 2020

Jennifer Woyach, MD, discusses the utility of time-limited therapies in chronic lymphocytic leukemia.

Dr. Woyach on Treatment Challenges in CLL

March 7th 2020

Jennifer Woyach, MD, discusses current challenges in chronic lymphocytic leukemia treatment.

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

February 20th 2020

Jennifer Woyach, MD, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia.

Dr. Woyach on the Design of the Ongoing Alliance A041702 Trial in CLL

February 5th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the design of the ongoing phase III Alliance A041702 trial in chronic lymphocytic leukemia (CLL).

Dr. Woyach on Ongoing Research With BTK Inhibitors in CLL

January 14th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Woyach on the Results of the ELEVATE-TN Trial in CLL

January 7th 2020

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Woyach on Frontline Treatment Options in CLL

January 3rd 2020

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

Dr. Woyach on 3-Year Follow-Up of Acalabrutinib/Obinutuzumab Combo in CLL

July 10th 2019

Jennifer Woyach, MD, discusses a 3-year follow-up looking at acalabrutinib with obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.

Dr. Woyach on Preliminary Efficacy Results of MOR208 Trial in CLL

February 7th 2017

Jennifer Woyach, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the preliminary efficacy results of the MOR208 trial in chronic lymphocytic leukemia (CLL).

Dr. Woyach on Ibrutinib Resistance in CLL

January 21st 2017

Jennifer Woyach, MD, associate professor, The Ohio State University, discusses ibrutinib resistance in patients with chronic lymphocytic leukemia.

Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL

December 7th 2016

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

September 18th 2014

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

July 15th 2014

Jennifer Woyach, MD, discusses the association of disease progression on ibrutinib therapy with the acquisition of resistance mutations.

Dr. Woyach on the Role of BTK in CLL

September 20th 2013

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's tyrosine kinase (BTK) in chronic lymphocytic leukemia (CLL).

Dr. Woyach on Ibrutinib and Peripheral Lymphocytosis

August 23rd 2013

Jennifer Woyach, MD, discusses peripheral lymphocytosis in patients with chronic lymphocytic leukemia after they take ibrutinib.